Alpha-fetoprotein and 18F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation

Journal of Hepatology

Volumn 64, Issue 4, 2016, Pages 852-859

  Hong, Geun ^a   Suh, Kyung Suk ^b   Suh, Suk Won ^b   Yoo, Tae ^b   Kim, Hyeyoung ^b   Park, Min Su ^b   Choi, Youngrok ^b   Paeng, Jin Chul ^c   Yi, Nam Joon ^b   Lee, Kwang Woong ^b  

^a Ewha Womans University School of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Alphafetoproteins; Biological factors; Fluorodeoxyglucose F18; Hepatocellular carcinoma; Liver transplantation; Living donors; Positron emission tomography

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY;

EID: 84958191688     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.11.033     Document Type: Article

References (27)

1. V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, F. Bozzetti, and et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699
2. F.Y. Yao, L. Ferrell, N.M. Bass, J.J. Watson, P. Bacchetti, A. Venook, and et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival Hepatology 33 2001 1394 1403
3. K.S. Suh, E.H. Cho, H.W. Lee, W.Y. Shin, N.J. Yi, and K.U. Lee Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria Dig Dis 25 2007 329 333
4. T. Ito, Y. Takada, M. Ueda, H. Haga, Y. Maetani, F. Oike, and et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation Liver Transpl 13 2007 1637 1644
5. A. Grasso, R. Stigliano, F. Morisco, H. Martines, A. Quaglia, A.P. Dhillon, and et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study Transplantation 81 2006 1532 1541
6. V. Mazzaferro, J.M. Llovet, R. Miceli, S. Bhoori, M. Schiavo, L. Mariani, and et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis Lancet Oncol 10 2009 35 43
7. C. Toso, S. Asthana, D.L. Bigam, A.M. Shapiro, and N.M. Kneteman Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database Hepatology 49 2009 832 838
8. G.C. Sotiropoulos, M. Malago, E. Molmenti, A. Paul, S. Nadalin, E. Brokalaki, and et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation 79 2005 483 487
9. S.A. Shah, J.C. Tan, I.D. McGilvray, M.S. Cattral, S.P. Cleary, G.A. Levy, and et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma Transplantation 81 2006 1633 1639
10. M.E. O'Malley, Y. Takayama, and M. Sherman Outcome of small (10-20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease Am J Gastroenterol 100 2005 1523 1528
11. R.B. Freeman, A. Mithoefer, R. Ruthazer, K. Nguyen, A. Schore, A. Harper, and et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database Liver Transpl 12 2006 1504 1511
12. N. Kneteman, T. Livraghi, D. Madoff, E. de Santibanez, and M. Kew Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation Liver Transpl 17 2011 S117 S127
13. P.A. Clavien, M. Lesurtel, P.M. Bossuyt, G.J. Gores, B. Langer, and A. Perrier Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report Lancet Oncol 13 2012 e11 e22
14. F. D'Amico, M. Schwartz, A. Vitale, P. Tabrizian, S. Roayaie, S. Thung, and et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria Liver Transpl 15 2009 1278 1287
15. S.H. Yang, K.S. Suh, H.W. Lee, E.H. Cho, J.Y. Cho, Y.B. Cho, and et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients Liver Transpl 12 2006 1655 1660
16. J.W. Lee, J.C. Paeng, K.W. Kang, H.W. Kwon, K.S. Suh, J.K. Chung, and et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma J Nucl Med 50 2009 682 687
17. A. Kornberg, M. Freesmeyer, E. Barthel, K. Jandt, K. Katenkamp, J. Steenbeck, and et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients Am J Transplant 9 2009 592 600
18. S. Merani, P. Majno, N.M. Kneteman, T. Berney, P. Morel, G. Mentha, and et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma J Hepatol 55 2011 814 819
19. K. Berry, and G.N. Ioannou Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma Liver Transpl 19 2013 634 645
20. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
21. C. Duvoux, F. Roudot-Thoraval, T. Decaens, F. Pessione, H. Badran, T. Piardi, and et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria Gastroenterology 143 2012 986 994
22. V. Mazzaferro Results of liver transplantation: with or without Milan criteria? Liver Transpl 13 2007 S44 S47
23. D. DuBay, C. Sandroussi, L. Sandhu, S. Cleary, M. Guba, M.S. Cattral, and et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion Ann Surg 253 2011 166 172
24. H. Furukawa, T. Shimamura, T. Suzuki, M. Taniguchi, K. Nakanishi, K. Yamashita, and et al. Liver transplantation for hepatocellular carcinoma: the Japanese experience J Hepatobiliary Pancreat Sci 17 2010 533 538
25. H. Mergental, R. Adam, B.G. Ericzon, P. Kalicinski, F. Muhlbacher, K. Hockerstedt, and et al. Liver transplantation for unresectable hepatocellular carcinoma in normal livers J Hepatol 57 2012 297 305
26. S. Sell Alpha-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer Tumour Biol 29 2008 161 180
27. S. Vallabhajosula (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization Semin Nucl Med 37 2007 400 419